Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking

Journal of Cystic Fibrosis

Volumn 14, Issue 1, 2015, Pages 16-25

  Carlile, Graeme W ^a   Robert, Renaud ^a   Goepp, Julie ^a   Matthes, Elizabeth ^a   Liao, Jie ^a   Kus, Bart ^b   Macknight, Sean D ^a   Rotin, Daniela ^b   Hanrahan, John W ^a   Thomas, David Y ^a  

^a MCGILL UNIVERSITY   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cystic fibrosis; NSAID; Protein folding; Protein trafficking

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IBUPROFEN; INDOMETACIN DERIVATIVE; LUMACAFTOR; MUTANT PROTEIN; N (3 PYRIDYL)INDOMETHACIN AMIDE; PROSTAGLANDIN SYNTHASE; SMALL INTERFERING RNA; SULFONYLUREA RECEPTOR 1; UNCLASSIFIED DRUG; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL POLARITY; CONTROLLED STUDY; DRUG TARGETING; EPITHELIUM CELL; GENE EXPRESSION; GENE SILENCING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; SALIVATION; SHORT CIRCUIT CURRENT; ANIMAL; CELL CULTURE; CELL MOTION; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; MUTATION; PROTEIN TRANSPORT; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ANIMALS; CELL MOVEMENT; CELLS, CULTURED; CYCLOOXYGENASE INHIBITORS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE MODELS, ANIMAL; HUMANS; IBUPROFEN; MICE; MICE, INBRED CFTR; MUTATION; PROTEIN TRANSPORT; REPRODUCIBILITY OF RESULTS; RNA, SMALL INTERFERING; SENSITIVITY AND SPECIFICITY;

EID: 84918785468     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.06.001     Document Type: Article

References (30)

1. Riordan J.R., Rommens J.M., Kerem B., Alon N., Rozmahel R., Grzelczak Z., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science Sep 8 1989, 245(4922):1066-1073.
2. Ward C.L., Omura S., Kopito R.R. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell Oct 6 1995, 83(1):121-127.
3. Jensen T.J., Loo W.A., Pind S., Williams D.R., Goldberg A.L., Riordan J.R. Multiple proteolytic systems including the proteosome, contribute to CFTR processing. Cell Oct 6 1995, 83(1):129-135.
4. Denning G.M., Andersen M.P., Amara J.F., Marshall J., Smith A.E., Welsh M.J. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature sensitive. Nature 1992, 358:761-764.
5. Carlile G.W., Keyzers R.A., Teske K.A., Robert R., Williams D.E., Linington R.G., et al. Correction of F508del-CFTR trafficking by the sponge alkaloid latonduine is modulated by interaction with PARP. Chem Biol October 19 2012, 26:1288-1299.
6. Robert R., Carlile G.W., Liao J., Balghi H., Lesimple P., Liu N., et al. Correction of the Delta phe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine. Mol Pharmacol 2010, 77:922-930.
7. Van Goor F., Straley K.S., Cao D., Gonzalez J., Hadida S., Hazelwood A., et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol Jun 2006, 290(6):L1117-L1130.
8. Clancy J.P., Rowe S.M., Accurso F.J., Aitken M.L., Amin R.S., Ashlock M.A., et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax Dec 16 2012, 67:12-18.
9. Konstan M.W., Vargo K.M., Davis P.B. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection: implications for anti-inflammatory therapy in cystic fibrosis. Am Rev Respir Dis 1990, 141:186-192.
10. Armstrong D.S., Grimwood K., Carlin J.B., et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997, 156:1197-1204.
11. Lands L.C., Milner R., Cantin A.M., Manson D., Corey M. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Ped 2007, 151(3):249-254.
12. 1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007, 176(11):1084-1089.
13. Smith C.J., Zhang Y., Kobolt C.M., Muhannad J., Zweifel B.S., Shaffer A., et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A 1998, 95:13313-13318.
14. Kakuta H., Fukai R., Xiaoxia Z., Ohsawa F., Bamba T., Hirata K., et al. Identification of urine metabolites of TFAP, a cyclooxygenase-1 inhibitor. Bioorg Med Chem Lett Mar. 15 2010, 20(6):1840-1843.
15. Grossman C.J., Wiseman J., Lucas F.S., Trevethick M.A., Birch P.J. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and Cox 2 inhibitors. Inflamm Res Jun 6 1995, 44:253-257.
16. Kalgutkar A.S., Marnett A.B., Crews B.C., Remmel R.P., Marnett L.J. Ester and amide derivatives of the nonsteriodal anti-inflammatory drug indomethacin as selective cyclooxygenase-2 inhibitors. J Med Chem 2000, 43(15):2860-2870. [Jul. 27].
17. - airway epithelial monolayers. J Physiol Dec 1 2005, 569(Pt2):601-615.
18. Sampson H.M., Lam H., Chen P.-C., Zhang D., Mottillo C., Mirza M., et al. Compounds that correct F508del-CFTR trafficking can also correct other protein trafficking diseases: an in vitro study using cell lines. Orphanet J Rare Dis 2013, 8:11.
19. Carlile G.W., Robert R., Zhang D., Teske K.A., Luo Y., Hanrahan J.W., et al. Correctors of protein trafficking defects identified by a novel high-throughput screening assay. Chembiochem 2007, 8:1012-1020.
20. Ostedgaard L.S., Rogers C.S., Dong Q., Randak C.Q., Vermeer D.W., Rokhlima T., et al. Processing and function of CFTR-DeltaF508 are species-dependent. Proc Natl Acad Sci U S A Sep. 25 2007, 104(39):15370-15375.
21. Wang X., Venable J., LaPointe P., Hutt D.M., Koulov A.V., Coppinger J., et al. Hsp90 cochaperone Aha1 down regulation rescues misfolding of CFTR in cystic fibrosis. Cell Nov 17 2006, 127(4):803-815.
22. - transport and overexpression can generate basolateral CFTR. Am J Physiol Lung Cell Mol Physiol 2005, 289:L1123-L1130.
23. Zhang L., Button B., Gabriel S.E., Burkett S., Yan Y., Skiadopoulos M.H., et al. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol 2009, 7:e1000155.
24. Van Goor F., Hadida S., Grootenhuis P.D., Burton B., Stack J.H., Straley K.S., et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A Nov 15 2011, 108(46):18843-18848.
25. Okiyoneda T., Veit G., Dekkers J.F., Bagdany M., Soya N., Xu H., et al. Mechanism-based corrector combination restores δF508-CFTR folding and function. Nat Chem Biol Jul 2013, 9(7):444-454.
26. - secretion. J Clin Invest August 15 1998, 102(4):679-687.
27. Li J., Xiang Y.Y., Ye L., Tsui L.C., Macdonald J.F., Hu W.Y. Nonsteroidal anti-inflammatory drugs upregulate function of wild-type and mutant CFTR. Eur Respir J Aug 2008, 32(2):334-343.
28. Dauletbaev N., Lam J., Eklove D., Iskandar M., Lands L.C. Ibuprofen modulates NF-kB activity but not IL-8 production in cystic fibrosis respiratory epithelial cells. Respiration 2010, 79(3):234-242.
29. Czerska K., Sobczynska-Tomaszewska A., Sands D., Nowakowska A., Bak D., Werthelm K., et al. Prostaglandin-endoperoxide synthase genest COX1 and COX2 - novel modifiers of disease severity in cystic fibrosis patients. J Appl Genet 2010, 51(3):323-330.
30. Tinsley H.N., Gary B.D., Keeton A.B., Lu W., Li Y., Piazza G.A. Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/beta catenin-mediated transcription in human breast tumor cells. Cancer Prev Res Aug 2011, 4(8):1275-1284.